ResearcherUniversity of Pittsburgh Medical CenterActive in the last 2 years

Hao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7261-9775; OpenAlex author ID A5100458864. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27595 ↗
CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08468-9 ↗
ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis. Co-author DOI 10.1245/s10434-020-08542-2 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amer H. Zureikat · 3 shared papers, 2020–2024 · strength 0.55
Hussein H. Khachfe · 1 shared paper, 2024 · strength 0.20
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595 ↗
Samer S. AlMasri · 1 shared paper, 2024 · strength 0.20
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595 ↗
Ibrahim Nassour · 1 shared paper, 2024 · strength 0.20
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595 ↗
Alessandro Paniccia · 1 shared paper, 2024 · strength 0.20
- Paper Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ducta… DOI 10.1002/jso.27595 ↗
Amr I. Al Abbas · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗
Melissa Ellen Hogg · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗
Caroline J. Rieser · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗
Herbert J. Zeh · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗
Nathan Bahary · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗
Aatur Dilip Singhi · 1 shared paper, 2020 · strength 0.11
- Paper CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreat… DOI 10.1245/s10434-020-08468-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.